Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2
Feasibility, Acceptability, and Preliminary Effectiveness of a Cognitive Behavioral Suicide Prevention-focused Intervention Tailored to Adults Diagnosed With Schizophrenia Spectrum Disorders: Aim 2 RCT
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lindsay A Bornheimer, PhD
- Phone Number: (734) 615-2915
- Email: bornheim@umich.edu
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Schizophrenia Spectrum Disorder
- Suicide ideation and/or attempt within 3 months of screening
- Ability to speak and read in English
- 18 to 65 years of age
Exclusion Criteria:
- Requiring emergency care (e.g. imminent plan to harm self) as determined by trained research staff administering the Columbia-Suicide Severity Rating Scale (C-SSRS)
- Inappropriate for behavioral treatment according to own judgment in consultation with a treating clinician CMH
- Impaired capacity (cognitive capacity)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cognitive Behavioral Suicide Prevention for psychosis (treatment group)
Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) is a behavioral treatment and will be delivered in 10 weekly individual therapy sessions in addition to standard/current services.
|
Cognitive and behavioral approach to suicide prevention tailored for individuals with psychosis
|
|
Active Comparator: Services as Usual (SAU; comparison group)
Services as usual involve standard and current services that clients are eligible for receiving.
|
Standard psychiatric and behavioral services provided at community mental health (e.g., case management, medication management)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Calgary Depression Rating Scale (CDRS)
Time Frame: 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
|
A scale to measure depression, higher scores indicate greater depression (range of 0-27)
|
4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
|
|
Positive and Negative Syndrome Scale (PANSS)
Time Frame: 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
|
A scale to measure psychosis symptoms, higher scores indicate greater psychosis (range of 30-210)
|
4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
|
|
Columbia Suicide Severity Rating Scale (C-SSRS)
Time Frame: 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
|
A scale to measure suicide thoughts and behavior, higher scores indicate greater suicide thoughts and behavior (range of 0-5)
|
4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Beck Hopelessness Scale
Time Frame: 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
|
A scale to measure hopelessness, higher scores indicate greater hopelessness (range of 0-20)
|
4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
|
|
Defeat Scale (D Scale)
Time Frame: 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
|
A scale to measure defeat, higher scores indicate greater defeat (range of 0-64)
|
4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
|
|
The Entrapment Scale
Time Frame: 4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
|
A scale to measure entrapment, higher scores indicate greater entrapment (range of 0-64)
|
4 time points (baseline, mid-treatment (1 month), post-treatment (3 months), and follow-up (5 months).
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HUM00211008
- R34MH123609 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.